These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21740298)

  • 1. Management of gram-positive bacterial infections in patients with cancer.
    Kosmidis CI; Chandrasekar PH
    Leuk Lymphoma; 2012 Jan; 53(1):8-18. PubMed ID: 21740298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of daptomycin in the treatment of infections in patients with hematological malignancies].
    Salavert M; Calabuig E
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():36-47. PubMed ID: 21477703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Update of antimicrobial resistance in Gram-positive microorganisms].
    Cercenado E
    Med Clin (Barc); 2010 Dec; 135 Suppl 3():10-5. PubMed ID: 21477699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ
    Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin.
    Jenkins I
    J Hosp Med; 2007 Sep; 2(5):343-4. PubMed ID: 17935250
    [No Abstract]   [Full Text] [Related]  

  • 7. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
    Smith PF; Booker BM; Ogundele AB; Kelchin P
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient.
    Schmidt-Ioanas M; de Roux A; Lode H
    Curr Opin Crit Care; 2005 Oct; 11(5):481-6. PubMed ID: 16175036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
    Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
    Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic.
    Corti G; Cinelli R; Paradisi F
    Int J Antimicrob Agents; 2000 Dec; 16(4):527-30. PubMed ID: 11118873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
    Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
    J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM; Jarvis B
    Drugs; 2001; 61(4):525-51. PubMed ID: 11324682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.
    Mendes RE; Deshpande LM; Jones RN
    Drug Resist Updat; 2014 Apr; 17(1-2):1-12. PubMed ID: 24880801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
    Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
    Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antibiotic agents: problems and prospects.
    Weber DJ; Rutala WA
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-97-107. PubMed ID: 23577500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of linezolid in children: an overview of recent advances.
    Velissariou IM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New anti-Gram+antibiotics: which role in infective endocarditis?].
    Makinson A; Le Moing V
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):88-92. PubMed ID: 18395180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.